Prescription

Loblaw Releases 2023 ESG Report

Retrieved on: 
Freitag, Mai 3, 2024
DEI, Food Banks Canada, Climate change, Atmosphere, Second Harvest Toronto, WWF-Canada, The Salvation Army, Vegetable, Nature, Woman, Health, TSX, Partnership, Carbon, Prescription, Kimberly-Clark, Food, Procter & Gamble, Greenhouse, ESG, Health equity, Organic, Meat

BRAMPTON, ON, May 3, 2024 /CNW/ - Loblaw Companies Limited (TSX: L) ("Loblaw") released its 2023 Environmental, Social, and Governance (ESG) report today.

Key Points: 
  • BRAMPTON, ON, May 3, 2024 /CNW/ - Loblaw Companies Limited (TSX: L) ("Loblaw") released its 2023 Environmental, Social, and Governance (ESG) report today.
  • In this our 17th ESG report we reflect on the achievements made in 2023."
  • Thank you, Loblaw, for the significant contributions which have made a such a positive impact across Canadian communities.
  • – Megan Leslie, President and CEO, World Wildlife Fund Canada
    To learn more about these initiatives and others like them, please visit https://www.loblaw.ca/en/responsibility/ and download a copy of the Loblaw Companies 2023 Environmental, Social and Governance Report.

Pet Supplies Plus & Wag N' Wash Commit to Helping 15,000 Dogs and Cats Get Adopted This Year

Retrieved on: 
Donnerstag, Mai 2, 2024
Pet, Animal, Prescription, Cat, Culture, Family, Food, Pet Supplies Plus, Dog, Pet industry

LIVONIA, Mich., May 2, 2024 /PRNewswire/ -- As more than six million pets are surrendered each year, there is a critical and immediate need for adoptions to take place across the U.S. To combat this growing issue, and in recognition of National Adopt a Shelter Pet Day (April 30), Pet Supplies Plus and Wag N' Wash have launched a nationwide initiative to help 15,000 dogs and cats get adopted in 2024. Year to date, the brands have helped more than 3,214 pets find their forever homes.

Key Points: 
  • Pet Supplies Plus + Wag N' Wash launch adoption initiative to share the value of and critical need for pet adoptions.
  • Part of each brand's identity and mission, Pet Supplies Plus and Wag N' Wash foster a culture of compassion for the well-being of all animals.
  • Pet Supplies Plus offers a wide array of natural pet foods and a variety of US-made pet consumables, including food, treats, rawhide and chews.
  • Each Wag N' Wash location offers both a self-serve pet wash station and full-service grooming salon.

AUA/SUFU Guideline on the Treatment of Overactive Bladder Allows Access to ReviTM System Earlier in Treatment Journey

Retrieved on: 
Montag, April 29, 2024
FDA, Commercial software, Society, Risk, Urinary incontinence, Food, De novo, American Urological Association, Paruresis, Pharmacotherapy, MMHC, Guideline, OAB, Deficit spending, Prescription, Patient, Neuromodulation, Physician, AUA, Ankle, Diagnosis, SUFU, Anticholinergic, Female

The revised guidelines are a major affirmation of the importance of Revi as a therapy for patients with UUI.

Key Points: 
  • The revised guidelines are a major affirmation of the importance of Revi as a therapy for patients with UUI.
  • First, the guidelines were updated to include iTNM as an acceptable minimally invasive therapy.
  • "We are delighted to witness the transformation of the new OAB treatment guideline by the AUA/SUFU.
  • This guideline represents a significant turning point in physicians' approach to OAB management," commented Dan Lemaitre, Chief Executive Officer of BlueWind Medical.

DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market

Retrieved on: 
Freitag, Mai 3, 2024
Telehealth, OTC, Prescription, Digital, Patient, CHF, Pharmacy, Growth

DocMorris continued the positive revenue trend of the previous quarter as planned in the first quarter of 2024.

Key Points: 
  • DocMorris continued the positive revenue trend of the previous quarter as planned in the first quarter of 2024.
  • External revenue [1] increased by 10.3 per cent in local currency compared to the same period of the previous year.
  • As at the end of March 2024, the number of active customers [2] increased by 600,000 to 9.7 million compared to the previous quarter.
  • TeleClinic, the leading platform for online doctor consultations in Germany, continued to grow very strongly in the first quarter of 2024.

EQS-News: Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.

Retrieved on: 
Freitag, Mai 3, 2024
Pharmacy, PIN, EUR, Plasma protein binding, Prescription, Smartphone, QR, Patient, Redcare, Sevenum, Pharmaceutical industry

Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.

Key Points: 
  • Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.
  • Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.
  • Today, Redcare Pharmacy has successfully obtained the provider approval by the gematik for its eHealth-CardLink solution, while its development partner eHealth Experts simultaneously received the product approval.
  • Customers of online pharmacies will still be able to use the gematik app or scan the QR code on the printed prescription.

Ascendis Pharma Reports First Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 2, 2024
FDA, Endocrine gland, Hypoparathyroidism, Element, GHD, Achondroplasia, Commercial, New Drug Application, Biologics license application, Development, Prescription, ASCO, Turner syndrome, PDUFA, Patient, Society, Melanoma, Vision, Inborn errors of metabolism, Pharmaceutical industry

If approved, U.S. launch planned in Q3

Key Points: 
  • If approved, U.S. launch planned in Q3
    — SKYTROFA® Q1 revenue more than doubled year-over-year to €65 million; Q1 operating expenses fell by 20% year-over-year to €137 million
    COPENHAGEN, Denmark, May 02, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • Plan to submit a supplemental Biologics License Application to FDA for adult growth hormone deficiency (GHD), in the third quarter of 2024.
  • Topline results from Phase 2 trial in Turner syndrome expected in the fourth quarter of 2024.
  • In the U.S., Prescription Drug User Fee Act (PDUFA) date of May 14, 2024; if approved, U.S. commercial launch planned in the third quarter of 2024.

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Retrieved on: 
Mittwoch, April 24, 2024
American Heart, FDA, Patient, HealthyWomen, University, Stroke, Professional corporation, Risk, Woman, Food, CVD, Health, Death, Fenofibrate, History, Prescription, Science, CFR, Commissioner, Cardiovascular disease, Clinical trial, Associate, Amarin, Medical director, Pharmaceutical industry

“Despite the many safe, effective, and FDA-approved treatments available on the market with clinically proven reductions of CVD risk, patients are still being treated with fenofibrates off-label.

Key Points: 
  • “Despite the many safe, effective, and FDA-approved treatments available on the market with clinically proven reductions of CVD risk, patients are still being treated with fenofibrates off-label.
  • This results in patients taking a drug proven to have no clinical benefit to reduce CVD risk,” said Nabil Abadir, M.D., Chief Medical Officer at Amarin.
  • “This is a significant issue that is risking patient health and should be addressed quickly by the FDA.
  • The petition also urges the FDA Commissioner to further clarify the position the agency previously took by removing the statin co-administration from fenofibrate labeling.

Mobile-health Network and Online Pharmacy, Lifepack, Sign Partnership Facilitating Cooperation in Singapore and Indonesia

Retrieved on: 
Dienstag, April 23, 2024
Practitioner, Telehealth, PBM, MNDR, Partnership, Prescription, Patient, Physician

The collaboration aims to improve healthcare accessibility in Indonesia by bringing affordable and accessible healthcare to the population.

Key Points: 
  • The collaboration aims to improve healthcare accessibility in Indonesia by bringing affordable and accessible healthcare to the population.
  • Under the partnership, approximately 2,000 Indonesian physicians, including general practitioners and specialists, will be on-boarded and trained to provide effective patient teleconsultations through MaNaDr's platform.
  • "This partnership will not only benefit Indonesian physicians and patients but also contribute to the advancement of telemedicine in the region."
  • We look forward to providing Indonesian residents with affordable, quality and 24x7 near-instant access to prescriptions and consultations with this partnership."

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

Retrieved on: 
Dienstag, April 23, 2024
American College, Investment, RESONANCE, Partnership, Webcast, Growth, Prescription, Patient, Patient satisfaction, ID, Pericarditis, Telephone, KNSA, Pharmaceutical industry

HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution.

Key Points: 
  • – ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –
    HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution.
  • Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023.
  • Total operating expenses for the first quarter of 2024 were $96.4 million, compared to $59.5 million for the first quarter of 2023.
  • Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 23, 2024, to discuss first quarter 2024 financial results and recent portfolio execution.

Inmar Intelligence Hosts 8th Medication Disposal Drive-Thru Event on April 27th

Retrieved on: 
Mittwoch, April 17, 2024
Intelligence, Novant Health, Risk, Human back, Plasma protein binding, Dust, Friends, Prescription, Family, Patient, Child, DEA, Abuse, Organization, Pharmaceutical industry

WINSTON-SALEM, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Inmar Intelligence is pleased to announce its 8th medication disposal drive-thru event on Saturday, April 27th from 10 am to 2 pm at Bolton Elementary School in Winston-Salem.

Key Points: 
  • WINSTON-SALEM, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Inmar Intelligence is pleased to announce its 8th medication disposal drive-thru event on Saturday, April 27th from 10 am to 2 pm at Bolton Elementary School in Winston-Salem.
  • Since hosting its first disposal event in 2019, Inmar has safely collected and disposed of over 2,800 pounds of medications from local homes.
  • However, the need for safe medication disposal is as important now as ever before.
  • “Novant Health is excited to partner with Inmar Intelligence to provide our patients and community with this safe, convenient medication disposal opportunity.